Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04057898 · ClinicalTrials.gov registry record · Phase 2
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by MediciNova.
- Active
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
- 16
- Study locations
NCT04057898 is a Phase 2 study of Amyotrophic Lateral Sclerosis that is active but no longer recruiting, run by MediciNova. The registered enrollment target is 234 participants, below the 896-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (74% lower). The trial reports 16 study locations across 15 states.
The verdict
NCT04057898, a Phase 2 study of Amyotrophic Lateral Sclerosis, is active but no longer recruiting, sponsored by MediciNova.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
- 16
- Study locations
Study Summary
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Conditions Studied
Interventions
- DRUG placebo
- DRUG MN-166
Study Locations (16)
Ontario
- McMaster University Medical Center - Hamilton
- Sunnybrook Research Institute - Toronto
California
- University of California - Orange
Florida
- Mayo Clinic - Jacksonville
Georgia
- Augusta University - Augusta
Indiana
- Indiana University IU Health Neuroscience Center - Indianapolis
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- Hennepin Healthcare Research Institute - Minneapolis
New York
- SUNY Upstate Medical University - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04057898
The ClinicalTrials.gov registry entry for NCT04057898 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 896-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (74% lower). The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT04057898 reports 16 study locations spanning 15 distinct geographic areas - top geographies include Ontario, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04057898 about?
NCT04057898 is a clinical study titled "Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS". A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
What is the current status of trial NCT04057898?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2020-05-28. Estimated completion is 2028-04.
What conditions does trial NCT04057898 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT04057898?
The interventions under investigation include: placebo (DRUG), MN-166 (DRUG).
Who is sponsoring clinical trial NCT04057898?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04057898 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.